2024-11-15T21:54:46-06:00 2023-12-31 873231666 PKF O'CONNOR DAVIES ADVISORY LLC 245 PARK AVENUE 12TH FLOOR NEW YORK NY 10167 990 2023-01-01 832004089 SINGULA INSTITUTE SING 2125315826 353 LEXINGTON AVENUE SUITE 600 NEW YORK NY 10016 MARC S LENER MD CHIEF EXECUTIVE OFFICER 2125315826 2024-11-15 1 1 EVA MRUK P00543254 2122862600 2024-11-15 2023 2024-10-15 13:58:12Z MARC S LENER MD 353 LEXINGTON AVENUE SUITE 600 NEW YORK NY 10016 364411 0 X WWW.SINGULAINSTITUTE.ORG X 2018 NY TO PERFORM RESEARCH ON CLINICAL CARE USING DATA AND TECHNOLOGY, CLINICAL MANAGEMENT, AND EDUCATION TO COMMUNITIES ABOUT MENTAL HEALTH. 10 10 0 20 0 0 238740 348588 0 0 0 0 0 15823 238740 364411 0 2500 0 0 95535 78512 0 0 17437 187671 233246 283206 314258 -44466 50153 153782 261065 2178 6416 151604 254649 X THE MISSION OF SINGULA INSTITUTE IS TO PROMOTE MENTAL HEALTH AND WELLNESS IN THE COMMUNITY THROUGH THE DEVELOPMENT OF A CLINICAL AND RESEARCH INSTITUTE TO UNDERSTAND AN INDIVIDUAL'S RISK FOR MENTAL ILLNESS AND TO TAILOR INTERVENTIONS BASED ON THE INDIVIDUAL'S UNIQUE COMBINATION OF BIOLOGICAL AND CLINICAL VARIABLES. USING SINGLE-SUBJECT RESEARCH DESIGN, WE PLAN TO USE INNOVATIVE COMPUTATIONAL METHODS, PSYCHOPHYSIOLOGICAL TESTS, AND CLINICAL ASSESSMENTS IN ORDER TO INTEGRATE AND EXTEND UPON EXISTING METHODS OF CLINICAL CARE (SPECIFICALLY, MEDICATIONS AND PSYCHOTHERAPY). WE ALSO PLAN TO BUILD A DATA REPOSITORY AND COLLABORATE WITH ACADEMIC AND NON-ACADEMIC PARTNERS TO IMPROVE TREATMENT ALTERNATIVES. 0 0 53062 2500 0 CLINICAL RESEARCH PROJECTS:OUR BOARD MEMBERS AND ADVISORS WORKED TOGETHER ON FURTHER DEVELOPING GOALS AND ANTICIPATED OUTCOMES OF CLINICAL RESEARCH AS PART OF A CLINICAL RESEARCH WORKING COMMITTEE. OUR MAIN CLINICAL RESEARCH PROTOCOL WAS SUBMITTED TO AND APPROVED BY OUR INSTITUTIONAL REVIEW BOARD AND PUBLISHED ON CLINICALTRIALS.GOV. 35375 0 0 HEALTHCARE OPERATIONS:INFORMATION TECHNOLOGY, HUMAN RESOURCES, FACILITIES, AND COMPLIANCE INFRASTRUCTURES WERE CREATED TO LAUNCH THE CLINICAL RESEARCH PROGRAM ALONGSIDE THE DEVELOPMENT OF BUSINESS DEVELOPMENT AND OPERATIONAL PLANS.*** IN 2023, WE INITIATED AND ENROLLED 7 TOTAL PATIENTS (4 MALES, 3 FEMALES), AGE RANGING BETWEEN 24-60 YEARS OLD FOR WEEKLY TO BIWEEKLY IN-PERSON SESSIONS. WE COLLECTED PATIENT-REPORTED OUTCOMES & AUDIO/VIDEO RECORDINGS IN BETWEEN EACH SESSION TO MEASURE INTERVAL CLINICAL PROGRESS. WE SIMULTANEOUSLY MANAGED 5 CLINICAL APPLICATIONS AND 10 EXTERNAL PORTALS TO OPERATIONALIZE THE CLINIC, PANELED WITH 3 INSURANCE PAYORS TO FACILITATE PATIENT ACCESS TO CARE (UNITED BEHAVIORAL HEALTH/OPTUM/OXFORD, CIGNA/EVERNORTH, AND AETNA). 34351 0 0 STUDENT INTERNSHIPS:UNDERGRADUATE AND GRADUATE STUDENT INTERNS HAVE WORKED WITH US COVERING A BROAD ARRAY OF INTERESTS AND NEEDS, SUCH AS PUBLIC HEALTH, HEALTHCARE BUSINESS, AND MARKETING AND COMMUNICATIONS. 4744 0 0 EDUCATIONAL RESOURCES:DR. MARC LENER AND THE MARKETING AND COMMUNICATIONS WORKING COMMITTEE CONTINUED TO CONTRIBUTE MEDICAL KNOWLEDGE TO A WIDE VARIETY OF PROFESSIONAL AND EDUCATIONAL ONLINE PUBLICATIONS AND PLATFORMS WHICH ARE DISTRIBUTED FREE TO THE PUBLIC ONLINE. 4744 0 0 127532 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 10 10 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 NY X X MARC S LENER MD 2125315826 353 LEXINGTON AVENUE SUITE 600 NEW YORK NY 10016 X MARC S LENER MD CEO 40.00 X X 0 0 0 BARRY PEEK ESQ CHAIR 2.00 X X 0 0 0 JOSHUA C RUBIN ESQ VICE CHAIR 3.00 X X 0 0 0 WILLIAM LANGDON SECRETARY 3.00 X X 0 0 0 CAROLINE LEE TREASURER 3.00 X X 0 0 0 KATHY ALIGENE MD DIRECTOR 1.00 X 0 0 0 DESMOND DODD DIRECTOR 3.00 X 0 0 0 ARVIND GOVINDARAJAN PHD DIRECTOR 1.00 X 0 0 0 RANDALL LEE DIRECTOR 1.00 X 0 0 0 KYLE SCHROEDER DIRECTOR 1.00 X 0 0 0 0 0 0 0 0 0 0 0 348588 348588 REFUND OF EXPENDITURES 900099 15823 15823 15823 364411 0 0 15823 X 2500 2500 72079 28832 43247 6433 2573 3860 18380 18380 109962 34351 62141 13470 4744 4744 5322 5322 1799 1799 49590 19836 25787 3967 8753 8753 DEVELOPMENT 27802 27802 CLINICAL RESEARCH 6894 6894 314258 127532 169289 17437 153782 261065 153782 261065 2178 6416 2178 6416 X 151604 254649 151604 254649 153782 261065 50153 52892 0 X 0 0 0 X 144218 121236 133647 238740 348588 986429 144218 121236 133647 238740 348588 986429 13000 15000 10500 126313 99100 263913 0 13000 15000 10500 126313 99100 263913 722516 15823 15823 144218 121236 133647 238740 364411 1002252 0.72090 0.74160 0.00000 X FORM 990, PART VI, SECTION A, LINE 2 MARC S. LENER AND KATHY ALIGENE HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION HAS ITS FORM 990 PREPARED BY AN OUTSIDE ACCOUNTING FIRM. THE FORM 990 IS REVIEWED BY THE CEO AND HEAD OF OPERATIONS. ONCE REVIEWED BY THE CEO AND HEAD OF OPERATIONS, A COPY IS PROVIDED TO ALL MEMBERS OF THE BOARD OF DIRECTORS FOR THEIR REVIEW AND COMMENT PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION HAS A CONFLICT OF INTEREST POLICY APPLICABLE TO DIRECTORS, OFFICERS, AND MEMBERS OF ANY COMMITTEES WITH DELEGATED POWERS FROM THE BOARD OF DIRECTORS. IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF THE FINANCIAL INTEREST AND BE GIVEN THE OPPORTUNITY TO DISCLOSE ALL MATERIAL FACTS TO THE DIRECTORS AND MEMBERS OF COMMITTEES WITH DELEGATED POWERS FROM THE BOARD OF DIRECTORS CONSIDERING THE PROPOSED TRANSACTION OR ARRANGEMENT. AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND ALL MATERIAL FACTS, AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, HE/SHE SHALL LEAVE THE BOARD OF DIRECTORS OR COMMITTEE MEETING WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. THE MINUTES OF THE BOARD OF DIRECTORS AND ALL COMMITTEES WITH BOARD-DELEGATED POWERS SHALL CONTAIN THE DISCUSSIONS AND DELIBERATION REGARDING AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST. EACH DIRECTOR, OFFICER AND MEMBER OF A COMMITTEE WITH POWERS DELEGATED BY THE BOARD OF DIRECTORS SHALL ANNUALLY SIGN A STATEMENT WHICH AFFIRMS SUCH PERSON: (A) HAS RECEIVED A COPY OF THIS CONFLICT OF INTEREST POLICY, (B) HAS READ AND UNDERSTANDS THE CONFLICT OF INTEREST POLICY, (C) HAS AGREED TO COMPLY WITH THE CONFLICT OF INTEREST POLICY, AND (D) UNDERSTANDS THAT THE ORGANIZATION IS CHARITABLE AND IN ORDER TO MAINTAIN ITS FEDERAL TAX EXEMPTION IT MUST ENGAGE PRIMARILY IN ACTIVITIES WHICH ACCOMPLISH ONE OR MORE OF ITS TAX-EXEMPT PURPOSES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS FORM 990, GOVERNING DOCUMENTS, AND CONFLICT OF INTEREST POLICY AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G PROJECT CONSULTANTS: PROGRAM SERVICE EXPENSES 34,351. MANAGEMENT AND GENERAL EXPENSES 62,141. FUNDRAISING EXPENSES 13,470. TOTAL EXPENSES 109,962.